3-D Matrix boosts its presence in the European market with a full calendar of GI events

The event season for 3-D Matrix is in full swing. Kicking off the series of events this autumn, it...

A new prospective observational registry (POPS) in the Middle East has launched in Kuwait

3-D Matrix is pleased to announce that a new prospective observational study (POPS) has started in ...

A new multicentre randomised controlled trial has started in Germany to evaluate PuraStat efficacy in preventing delayed bleeding after endoscopic resections.

The clinical investigation “Prospective, multicentre randomised controlled trial of the...

PuraStat becomes PuraBond for cardiac surgeons in Spain

In conjunction with its participation at the XXVI edition of the Secce’s congress in Oviedo, 3-D...

The Global PuraStat Dinner Grandior Hotel Prague on Thursday 28th April 2022

On Thursday 28th April 2022, 3-D Matrix, in collaboration with FUJIFILM, hosted their first global ...

3-D Matrix ranked in the Top 500 Fastest Growing Companies in Asia-Pacific region published by Financial Times

We are pleased to share that 3-D Matrix has been ranked 179th on the list of the 500...

Meet the Expert in Germany -  PuraStat: Looking Beyond Haemostasis

On the 23rd of February, 3-D Matrix continued its Meet the Expert series with "PuraStat: Looking...

Controlled Trial to Evaluate the Efficacy of PuraStat in Reducing  Delayed Bleeding (in high-risk patients) After Colonic Endoscopic Submucosal Dissection Has Started in France.

The new clinical trial “Multicentre Randomised Controlled Trial (RCT) to assess the efficacy of a...

First Human Clinical Investigation of the Next Generation Self-Assembling Haemostat [in progress]

The clinical investigation ‘First-in-Human Trial of the Safety and Performance of NU-MAX® as a...

Global news: Japan Published Their First PuraStat Case Report

Last month, the first PuraStat case report in Japan was published. Written by Dr Takuto Hikichi (...